I agree, a lot of unsophisticated retail holding rac. If these options really are to benefit/reward ALL holders, then any shortfall should be binned and raised at a higher price.
I'm going to be filthy if it goes to insiders yet to put their hands in their pockets or to a fund (without vesting conditions)...
The Oncolines data released last week warrants abandoning the AML trial altogether, in favour of a Zan + Decitabine basket trial.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)